Viatris Inc (VTRS) FinancialsVTRSViatris Inc

Viatris Inc. (VTRS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Brands, accounting for 64.6% of total sales, equivalent to $2.42B. Another important revenue stream is Generics. Understanding this composition is critical for investors evaluating how VTRS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Viatris Inc. maintains a gross margin of 42.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.60%, while the net margin is -3.16%. These profitability ratios, combined with a Return on Equity (ROE) of -2.75%, provide a clear picture of how effectively VTRS converts its operational activities into shareholder value.

In the context of the broader market, VTRS competes directly with industry leaders such as INSM and INCY. With a market capitalization of $21.43B, it holds a significant position in the sector. When comparing efficiency, VTRS's gross margin of 42.03% stands against INSM's 83.76% and INCY's 93.73%. Such benchmarking helps identify whether Viatris Inc. is trading at a premium or discount relative to its financial performance.

Viatris has shown a strong year-to-date performance with a 44.46% increase, and a 72.74% increase over the past year. The gross margin has improved to 42.03% in Q2 2026, suggesting better profitability.